Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

we generated $170.7 million in cash flow from operations and deployed $170.0 million to repurchase 9.2 million shares during 2011.

Looking ahead in 2012ViroPharma is reiterating its guidance for the year 2012 as a convenience to investors.  The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties.  For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2012, ViroPharma expects the following:

  • Worldwide net product sales are expected to be $600 to $660 million;
  • Net U.S. Cinryze sales are expected to be $310 to $330 million;
  • Net Vancocin sales are expected to be $260 to $310 million; and
  • Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to be $230 to $260 million.

  • Non-GAAP DisclosuresThe Company is reporting both GAAP net income  and non-GAAP adjusted results for the three and twelve months ended December 31, 2011 and 2010.   Non-GAAP adjusted net income is GAAP net income excluding (1) non-cash interest expense, (2) amortization related intangible assets acquired, (3) stock compensation expenses, and (4) certain non-recurring events. Non-GAAP adjusted diluted net income per share reflects the Non-GAAP adjusted net income, after the incremental effect of applying the "if converted" method of accounting to the senior convertible notes, and the diluted shares used in determining our GAAP diluted net income per share. A reconciliation between GAAP and non-GAAP adjusted measures is provided in the Selected Financial Information – Non-GAAP Financial Measures Reconciliation table included with this release. The Company believes that its presentation of historical non-GAAP financial measure
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/30/2015)... SureClinical, a leader in cloud-based health ... joined SureClinical’s executive team as Chief Financial Officer. ... executive with over 25 years in leadership roles ranging ... Ms. Morris joins SureClinical from Marrone Bio Innovations (MBI), ... of MBI from its founding in 2006 until 2011, ...
    (Date:4/29/2015)... 2015 According to a new ... Product (Portable & Non-Portable), Component (Accelerometer, Proximity Probe, ... Metal & Mining, & Others), & Geography - ... expected to reach $1,453.76 Million by 2020, at ... data tables and 92 figures spread through 205 ...
    (Date:4/29/2015)... , April 29, 2015   Doximity , the ... all US doctors as members, announced a new, instant ... "Apply Using Doximity." With one click, all US physicians ... curriculum vitae (CV) for an open job opportunity, and ... Eighty seven percent of physicians are open ...
    (Date:4/29/2015)... Poway, CA (PRWEB) April 29, 2015 ... proud to announce that its regenerative stem cell therapy ... founded in 2002, seeking to discover a successful treatment ... ligaments. , In 2003 VetStem signed a worldwide exclusive ... veterinary application, and the first horse was treated in ...
    Breaking Biology Technology:Julie I. Morris Joins SureClinical as Chief Financial Officer 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4Doximity Offering Hospitals Easy, Efficient Physician Application Tool 2VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2
    ... 27 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... a live webcast and conference call of presentations made ... Society of Clinical Oncology Annual Meeting (ASCO) on Saturday, ... p.m. EDT. , During the reception, OncoGenex management and ...
    ... including the mentally ill, the disabled and ethnic minorities ... than others in the aftermath of natural disasters, suffering ... Now, a new study by UCLA researchers and colleagues ... and make more behavioral changes based on those fears ...
    ... the origin and time of an aerosolized release of ... few cases has been developed by researchers from the ... Modelling at Imperial College London in collaboration with the ... The method, described in an article published April 10 ...
    Cached Biology Technology:OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009 2Disabled and other vulnerable groups more susceptible to terrorism fears 2Novel method predicts impact of a covert anthrax release 2
    (Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
    (Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
    (Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
    Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2
    ... are an invaluable part of the marine ecosystem, fostering ... Pathogenic bacteria, along with pollution and harmful fishing practices, ... coral populations today. One of the solutions ... Eugene Rosenberg of Tel Aviv University,s Department of Molecular ...
    ... but they are also necessary. Researchers at the University ... invention that makes clinical trials more efficient by moving ... Bank," the computer software eye modeling program includes data ... their inventions. Developed by Ying-Ling Chen, research assistant professor ...
    ... who are highly exposed to common environmental chemicals - ... at birth and larger at 20 months of age, ... of Public Health published online in the August 30 ... are used in the production of fluoropolymers and are ...
    Cached Biology News:Viruses could be the key to healthy corals 2University of Tennessee Space Institute researchers make clinical trials a virtual reality 2Chemical exposure in the womb from household items may contribute to obesity 2
    Rabbit polyclonal to hnRNP-U...
    ... DNase I (RNase-free) (E.C. 3.1.21.1) is ... DNA and chromatin. It functions by hydrolyzing ... a 5'-phosphate and a 3'-hydroxyl group. Ambion's ... purity available and is recommended to degrade ...
    ... a unique β-agarose digesting enzyme developed at ... DNA and RNA from low melting point ... TBE, MOPS, or phosphate buffers. The gel ... TBE, MOPS, and phosphate electrophoresis buffers or ...
    ... Perhaps sheer in-house demand is causing shortages in ... antibody. This can cause unwanted distractions, problems and ... for your hard work and endeavour! Bring us ... and market it internationally. We work under ISO ...
    Biology Products: